-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LZS2FYS3d8LASR64NfgStFtYFesNfZ+vvwYwZ8fkjxDVhdbqzkCmakI7TPzGjx8J obh4MFEL+qqjxvKctjrK8A== 0001140361-11-005845.txt : 20110203 0001140361-11-005845.hdr.sgml : 20110203 20110203114353 ACCESSION NUMBER: 0001140361-11-005845 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110201 FILED AS OF DATE: 20110203 DATE AS OF CHANGE: 20110203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NAQUI ALI CENTRAL INDEX KEY: 0001350577 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19271 FILM NUMBER: 11569142 MAIL ADDRESS: STREET 1: C/O IDEXX IDEXX LABORATORIES, INC. STREET 2: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDEXX LABORATORIES INC /DE CENTRAL INDEX KEY: 0000874716 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 010393723 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 BUSINESS PHONE: 2075560300 MAIL ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 FORMER COMPANY: FORMER CONFORMED NAME: IDEXX CORP / DE DATE OF NAME CHANGE: 19600201 4 1 doc1.xml FORM 4 X0303 4 2011-02-01 0 0000874716 IDEXX LABORATORIES INC /DE IDXX 0001350577 NAQUI ALI ONE IDEXX DRIVE WESTBROOK ME 04092 0 1 0 0 Corporate Vice President Common Stock 2011-02-01 4 M 0 3678 28.655 A 19686 D Common Stock 2011-02-01 4 M 0 3230 25.45 A 22916 D Common Stock 2011-02-01 4 S 0 1678 72.2403 D 21238 D Common Stock 2011-02-01 4 S 0 3230 72.2111 D 18008 D Incentive Stock Option (right to buy) 28.655 2011-02-01 4 M 0 3678 0 D 2015-02-02 Common Stock 3678 0 D Non-Qualified Stock Option (right to buy) 25.45 2011-02-01 4 M 0 3230 0 D 2014-02-04 Common Stock 3230 0 D The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $72.22 to $72.2746, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $72.21 to $72.235, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range. Grant of options to buy shares of common stock becomes exercisable as to 1,358 shares on 2/3/2009 and the remaining 2,320 shares on 2/3/2010. Grant of options to buy shares of common stock becomes exercisable as to 2,400 shares on 2/5/2005, 2/5/2006 and 2/5/2007, and the remaining 1,030 shares on 2/5/2008. John B. Rogers, Attorney-in-Fact for Ali Naqui, PhD 2011-02-03 -----END PRIVACY-ENHANCED MESSAGE-----